1. ADIL MEHMOOD - Department of Hepatobiliary and Echinococcus Surgery, Digestive and Vascular Surgery Center, First
Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
2. SHAO YING MEI - Department of Hepatobiliary and Echinococcus Surgery, Digestive and Vascular Surgery Center, First
Affiliated Hospital of Xinjiang Medical University, 393, Xinyi road Urumqi, Xinjiang, China, Clinical Medical
Research Center of Echinococcus and Hepatobiliary Disease of Xinjiang Uygur Autonomous Region,
Urumqi, China.
3. ABUDUHAIWAIER ABUDUHELILI - Department of Hepatobiliary and Echinococcus Surgery, Digestive and Vascular Surgery Center, First
Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
4. YANG YUHANG - Department of Hepatobiliary and Echinococcus Surgery, Digestive and Vascular Surgery Center, First
Affiliated Hospital of Xinjiang Medical University, Urumqi, China.
This review covers various aspects of echinococcosis in humans, including the biology, life cycle, etiology, distribution, and transmission of Echinococcus organisms. Additionally, it discusses the epidemiology, clinical features, treatment options, and the impact of improved diagnosis on the diseases they cause. Despite some advances in echinococcosis control, this zoonotic disease remains a significant public health challenge in many countries, including China & Pakistan. Moreover, in several other regions, it is considered both an emerging and re-emerging disease, indicating its persistent threat to human and animal health. No alternative drug to albendazole exists for treating echinococcosis, necessitating urgent development of new compounds. Genomic and proteomic data offer promise for enhancing diagnosis and identifying drug and vaccine targets, which could significantly impact echinococcosis control in the future, addressing its persistent global challenge.
Echinococcosis, Cystic Echinococcosis (CE), Alveolar Echinococcosis (AE).